1. Home
  2. FBDT vs RNTX Comparison

FBDT vs RNTX Comparison

Compare FBDT & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Breach Inc. Common Stock

FBDT

First Breach Inc. Common Stock

N/A

Current Price

$0.85

Market Cap

48.4M

Sector

Industrials

ML Signal

N/A

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.35

Market Cap

50.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBDT
RNTX
Founded
2018
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Ordnance And Accessories
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.4M
50.9M
IPO Year
2026
2017

Fundamental Metrics

Financial Performance
Metric
FBDT
RNTX
Price
$0.85
$0.35
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $6.00
AVG Volume (30 Days)
212.2K
★ 899.0K
Earning Date
11-16-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 44.16
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.28
52 Week High
$1.25
$2.10

Technical Indicators

Market Signals
Indicator
FBDT
RNTX
Relative Strength Index (RSI) 45.70 24.57
Support Level $0.73 N/A
Resistance Level $1.03 $0.91
Average True Range (ATR) 0.08 0.07
MACD -0.01 -0.03
Stochastic Oscillator 17.22 15.43

Price Performance

Historical Comparison
FBDT
RNTX

About FBDT First Breach Inc. Common Stock

First Breach Inc is an American defense technologies company focused on manufacturing match-grade ammunition components, finished ammunition, and developing unmanned aerial systems for commercial, law enforcement, and military markets. Its ammunition operations include the in-house production of brass cups, casings, projectiles, lead cores, lead wire, and completed ammunition. The company is also developing U.S.-made unmanned aerial systems incorporating robotics, intelligence, surveillance and reconnaissance (ISR), sensor, and precision manufacturing technologies for defense, homeland security, law enforcement, and commercial applications.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: